PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
NCT07739537 on ClinicalTrials.gov · last registry update 2026-08-31
Registered but not yet open, with 100 participants planned. Due to report 30 September 2029, alongside 12 other tracked readouts that quarter. Primary outcome, as filed: Physiologic characterization by MMTT. Sponsors move these dates routinely; any movement since this site started watching is listed below.
- Status
- NOT_YET_RECRUITING
- Phase
- P4
- Drug
- orforglipronFoundayo
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Other
- Enrollment
- 100
- Started
- 2026-10-01
- Primary completion
- 2029-09-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Physiologic characterization by MMTT
Conditions studied
Diabete Type 2 · Pharmacogenomic Drug Interaction
Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.